BPC-157 in Cell-Based Endothelial Models: What the In Vitro Literature Reports

Interest in BPC-157 within cell-culture research centres on vascular endothelial readouts. In a study combining a rodent injury model with cell work, cultured human umbilical vein endothelial cells (HUVECs) exposed to BPC-157 showed increased proliferation as measured by MTT assay and cell cycle analysis [1]. The same in vitro work reported that transwell and scratch wound-healing assays registered greater HUVEC migration in the BPC-157 condition than in controls [1]. Tube formation assays in the same cell system were reported to proceed more rapidly under BPC-157 exposure, and the authors reported upregulated VEGF-a expression in the cultured cells [1]. The mechanistic arm of that in vitro work examined signalling intermediates rather than clinical endpoints. The investigators reported that BPC-157 altered the phosphorylation state of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and of downstream transcriptional targets including c-Fos, c-Jun and Egr-1, which the authors described as molecules associated with cell growth, migration and angiogenesis in culture [1]. These are cell-culture observations and were not measured in human subjects [1]. The in vitro findings in that report sat alongside an animal arm. In a rat alkali-burn skin model, topical BPC-157 was reported to accelerate wound closure, with histological sections at day 18 post-wounding showing differences in granulation tissue formation, re-epithelialisation, dermal remodelling and collagen deposition relative to the model control group, together with vascular endothelial growth factor expression in the wounded tissue [1]. This arm was conducted in rats and does not constitute a human result [1]. A narrative review placed this class of observation in the context of the standard angiogenic growth factors EGF, FGF and VEGF, comparing how each has been studied in gastrointestinal tract healing and in tendon, ligament, muscle and bone healing models [2]. The review noted that for the standard growth factors the tendon, muscle and bone literature consists largely of reports of their increased presentation alongside injury procedures, with comparatively fewer in vitro studies and a limited number of in vivo healing studies often restricted to local application with varied carriers and delivery systems [2]. The authors reported that BPC-157 was, in the studies they surveyed, examined as a free peptide without a carrier across esophageal, gastric, duodenal and lower gastrointestinal injury models as well as tendon, ligament and bone models in animals [2]. The review is a secondary synthesis of preclinical literature and reports no human trial data [2]. One boundary of the retrieved evidence should be stated plainly for researchers scoping this area: the studies retrieved here characterise endothelial cell cultures, specifically HUVECs, and do not report fibroblast monoculture experiments [1]. Statements about connective tissue remodelling in the retrieved set derive from histological scoring of rodent tissue and from the review's survey of animal tendon, ligament, muscle and bone models, not from isolated fibroblast assays [1][2].